MiniMed Group MMED Italy — Increase (Decrease) In Contract With Customer, Refund Liability

Similar metrics at other companies

MDTITALY — Increase (Decrease) in Contract with Customer, Liability

-$39M—

DECKContract With Customer, Refund Liability, Increase (Decrease) For Change In Estimated Sales Returns, Net

$59.26M+45.6%

PLUGIncrease Decrease In Customer Liability

-$2.36M+89.1%

TEMIncrease Decrease In Contract With Customer Liability Other

-$3.99M0.0%

LRNIncrease Decrease In Contract With Customer Liability And Other Liabilities

-$13.77M+12.2%

OSISIncrease Decrease In Contract With Customer Liability Customer Deposits And Prepayments

-$3.53M—

Other financials

Income statement

See full

Revenue$790.0M+15.0%

Gross profit$362.0M-8.4%

Operating income-$100.0M-576%

Net income-$119.0M-1,090%

EPS (diluted)-$0.47-1,075%

Balance sheet

See full

Cash & equivalents$10.0M0.0%

Total debt$61.0M—

Total equity$3.5B-0.7%

Total assets$4.3B—

Cash flow

See full

Operating cash flow-$27.0M-147%

CapEx$167.0M+22.8%

Free cash flow-$194.0M-146%

Valuation

See full

Market cap$3.86B—

Returns & leverage

See full

Debt / equity0×—

Current ratio1.6×—

Where this comes from

Reported directly by MiniMed Group in its filing.

Tagged under the XBRL concept mdt:IncreaseDecreaseInContractWithCustomerRefundLiability.

The official record: MiniMed Group ’s 10-Q, filed April 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiniMed Group 's italy — increase (decrease) in contract with customer, refund liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MiniMed Group 's italy — increase (decrease) in contract with customer, refund liability?: MiniMed Group (MMED) reported italy — increase (decrease) in contract with customer, refund liability of -$7M in Q1 2026.
What does italy — increase (decrease) in contract with customer, refund liability mean?: This metric represents the net change in the obligation to refund customers for returned medical devices or services within the Italian market. It reflects management's estimate of potential future returns and price concessions that reduce the expected transaction price. Monitoring this helps investors assess the stability of revenue recognition and the quality of sales within the region.